Objective measures can be measured consistently. Examples are heart rate, eye blink rate, or counting how many times a person can catch a ball tossed from 3 feet away.
Related Articles:
- Fragile X Research: How Close Are We to a Cure?Discover the latest in Fragile X research at FRAXA. Learn how groundbreaking treatments, clinical trials, and gene therapies are moving us closer to a cure for Fragile X syndrome.
- Recruiting: Clinical Study of Non-Invasive EEG for Children Ages 2-7Dr. Carol Wilkinson, MD PhD, and Dr. Charles Nelson, PhD, at Boston Children’s Hospital are recruiting children ages 2-7 years with Fragile X syndrome to participate in a study of brain differences using non-invasive EEG.
- Finding Fragile X Biomarkers – From Transcriptomics to Behavior in PatientsWith this $20,000 award from FRAXA Research Foundation, Dr. Vanderklish and collaborators at Scripps Research Institute, the University of Chile, and the FLENI Institute in Argentina are analyzing patterns in gene expression in blood cells of patients with Fragile X syndrome. They are using "transcriptomics" which can produce a time-sensitive signature of an individual person. This is the first time that all these different levels of study – from transcriptomics to behavior – have been done for individual patients with Fragile X.
- Overcoming the Placebo Effect in Fragile X Clinical TrialsIn a placebo-controlled clinical trial, some participants are given an experimental medication, while others are given a placebo. Participants do not know whether they are taking medicine or placebo. In theory, this can allow researchers to rule out the placebo effect by comparing outcomes among the two groups. But, per Wexler (2020) “having a strong placebo effect can obscure any real effect of the therapy being investigated”.
- Alternative Splicing in White Blood Cells: A Biomarker for Fragile X SyndromeExplore groundbreaking research by the University of Massachusetts Medical School and Rush University Medical Center on alternative splicing in white blood cells as a biomarker for Fragile X syndrome, paving the way for personalized treatment optimization through a non-invasive blood test.